biotech, consumer health, GSK, Haleon, IPO, listing, London, pharma, split, stock exchange GSK splits off consumer health as Haleon... GlaxoSmithKline (GSK), one of the UK’s large pharma player, has voted to spin-off its consumer healthcare business into a new company called Haleon. Shareholders gave the go-ahead for GSK … more ➔
Polpharma Biologics Announces EMA Accept... European Medicines Agency (EMA) has accepted the application for biosimilar natalizumab, a proposed biosimilar to Tysabri® (Biogen) in the indication of Multiple Sclerosis (MS). more ➔
Agomab extenses Series B with USD40m Bri... Agomab Therapeutics NV from Ghent, Belgium, today announced it has extended its Series B financing round with an additional close of $40.5 million (€38.4 million), bringing the total Series B amount … more ➔
Spatial Biology Company Navinci (Olink)... Navinci Diagnostics AB, a Swedish life science company formerly known as Olink developing innovative tools for spatial proteomics research, announces the closing of SEK 90 million financing. The round … more ➔
ADC, cancer, Chris Martin, Lausanne, orphan, Sobi, Swedish, Zynlonta Swedish SOBI awarded rights to market Zy...In a deal worth around USD435m Swiss ADC therapeutics grants Swedish Orphan Biovitrum (SOBI) the rights to market freshly approved Zynlonta outside the US. more ➔
bioeconomy, biosyntia, bonn, brandkamp, circular, denmark, ECBF, financing, fund ECBF joins Novo Seeds and Sofinnova Part...The European Circular Bioeconomy Fund (ECBF) expands its industrial biotechnology portfolio by joining the financing Series B of danish Biosyntia ApS. Biosyntia is a precision fermentation company focused … more ➔
Lonza invests CHF500m in Large-Scale Fac... Large CDMO Lonza to build a new large-scale, commercial drug product facility including fill and finish to support customers across the entire product life cycle in Switzerland, investment of CHF500m. more ➔
Evotec, Boehringer Ingelheim, and bioMér...Evotec, pharma giant Boehringer Ingelheim, and IVD specialist bioMérieux have launched a €40m joint venture to fight Antimicrobial Resistance (AMR). more ➔
Urovant Sciences cashes in $75m in licen...French drugmaker Pierre Fabre Médicaments will pay $75m for an exclusive licence to to commercialise Urovant Sciences’ drug vibegron for the treatment of overactive bladder in Europe. more ➔
CureVac NV sues BioNTech for IP infringe...German mRNA vaccine developer CureVac, whose COVID-19 vaccine was not effective, on Monday sued BioNTech/Pfizer for infringement of four patents. more ➔
